Internal Medicine
RSSArticles
-
Subtle but Real?
The electrocardiogram (ECG) in the figure was obtained from an older man with intermittent chest pain that has awakened him from sleep. How would you interpret this ECG? Should you activate the cath lab?
-
Suzetrigine Tablets (Journavx)
The U.S. Food and Drug Administration has approved suzetrigine, a first-in-class, non-opioid analgesic, to treat moderate to severe pain.
-
Treating Hereditary TTR Amyloid Polyneuropathy with Patisiran
A five-year study on patisiran for hereditary transthyretin (TTR) amyloid polyneuropathy found that 65% of patients had stable or improved neuropathy, with better outcomes linked to early treatment. Despite efficacy, 19.4% of patients died. The study underscores the importance of early diagnosis and intervention in managing this progressive disease.
-
Cardiac and Paracardiac Structure in the SUMMIT Trial
A cardiac magnetic resonance imaging study in a subgroup of the patients in the SUMMIT trial of tirzepatide in patients with heart failure with preserved ejection fraction has demonstrated that patients treated with tirzepatide had reduced left ventricular mass and paracardiac adipose tissue compared to placebo-treated patients, which may partially explain the reduction in heart failure events observed in the main SUMMIT trial.
-
Magnetic Stimulation and Tai Chi for Older Adults with Sleep Disorders and MCI
This study showed improvement in sleep and cognitive endpoints in patients with sleep disorders and mild cognitive impairment (MCI) treated with a combination of repetitive transcranial magnetic stimulation and tai chi chuan.
-
RSV Vaccination in Severely Immunocompromised Individuals
The antibody response to respiratory syncytial virus vaccination is significantly impaired in many severely immunocompromised individuals.
-
Olezarsen Injection (Tryngolza)
The U.S. Food and Drug Aministration has approved olezarsen, a first-in-class drug to reduce triglycerides in adults with familial chylomicronemia syndrome. Olezarsen is an antisense oligonucleotide-directed inhibitor of apolipoprotein C-III messenger ribonucleic acid.
-
Noninferiority of Seven vs. 14 Days of Antibiotic Therapy for Bloodstream Infections
In this multinational, noninferiority trial that included more than 3,600 hospitalized patients with bloodstream infections from various pathogens and infectious syndromes, seven days of antibiotic therapy was noninferior to 14 days with respect to death from any cause by 90 days. Patients were excluded if they had severe immunosuppression or foci requiring prolonged treatment, or if their blood cultures yielded Staphylococcus aureus or possible contaminants. Various secondary outcomes were similar between the two groups.
-
Procalcitonin-Guided Care Leads to Shorter Duration of Antibiotics in Sepsis
In this multicenter, intervention-concealed, randomized clinical trial of 2,760 critically ill patients hospitalized with sepsis, the use of a daily procalcitonin-guided protocol resulted in shorter antibiotic duration as compared with standard care, without a significant difference in 28-day all-cause mortality. There was no significant difference in antibiotic duration between patients managed with a daily C-reactive protein-guided protocol and standard care, and the difference in all-cause mortality between these two groups was inconclusive.
-
Migraine and Ischemic Vascular Disease: The Search for the Missing Link
The presence of traditional vascular risk factors does not explain the increased incidence of ischemic stroke and myocardial infarction in patients with migraine. The use of nonsteroidal anti-inflammatory drugs does not increase the risk of ischemic stroke or myocardial infarction in migraineurs.